Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sable Offshore Corp. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][5]. Group 1: Class Action Details - The Class Period for the securities class action is defined as between May 19, 2025, and June 3, 2025, inclusive, and includes those who participated in Sable's secondary public offering on May 21, 2025 [1]. - Investors who purchased Sable securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 26, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Sable Offshore Corp. made materially false and misleading statements regarding the restart of oil production off the coast of California, which were not true [5]. - As a result of these misleading statements, investors suffered damages when the true information became public [5].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of shareholders who purchased securities between August 10, 2023, and June 25, 2025, alleging that the company misrepresented the results of its IMPACT Phase 2b MASH trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Altimmune created a false impression regarding the reliability of information related to the IMPACT Phase 2b MASH trial results, specifically failing to meet a key statistical significance marker for fibrosis reduction [4]. - Altimmune allegedly inflated expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the topline results [4]. - When the true results were disclosed, investors reportedly suffered damages due to the misleading information provided by Altimmune [4]. Group 2: Participation Information - Shareholders who purchased Altimmune securities may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs are required [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][5]. - A lead plaintiff must file a motion with the court by October 6, 2025, to represent other class members in the litigation [1][3].

Core Points - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities between October 9, 2024, and July 10, 2025, of the lead plaintiff deadline on September 15, 2025 [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [2] - A class action lawsuit has been filed, and interested parties can join by contacting the firm or visiting their website [3] Case Details - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [5] - Defendants allegedly made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from the Phase 2 HOPE-2 trial [5] - The misleading information is claimed to have caused shareholders to purchase securities at inflated prices, leading to damages when the truth was revealed [5] Rosen Law Firm's Credentials - The firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has recovered hundreds of millions for investors [4] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4]

Group 1 - The Rosen Law Firm is reminding purchasers of Neogen Corporation common stock from January 5, 2023, to June 3, 2025, about the September 16, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Neogen common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - A class action lawsuit has already been filed, and interested parties must move the Court by September 16, 2025, to serve as lead plaintiff [2] Group 2 - The lawsuit alleges that Neogen's defendants made false and misleading statements regarding the integration process, leading investors to believe it was progressing smoothly [4] - Initially, defendants claimed the integration was "off to a great start" and that Neogen was experiencing solid core growth and profitability [4] - Despite admitting to certain "inefficiencies" during the integration, defendants downplayed these issues, assuring investors they were committed to resolving them [4] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, the firm secured over $438 million for investors, and it has been consistently ranked among the top firms for securities class action settlements since 2013 [3]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which did not meet key statistical significance markers [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - The lawsuit claims that Altimmune created a false impression of reliable information regarding trial results, while concealing negative data that would impact the topline results [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for investors [4]. - Investors wishing to serve as lead plaintiff must file their motion by October 6, 2025 [1][3]. Group 3: Trial Results - Altimmune's IMPACT Phase 2b MASH trial failed to achieve statistical significance for the primary endpoint related to fibrosis reduction, contrary to the company's previous claims [5]. - The lawsuit alleges that the company concealed higher responses in the placebo group, which negatively affected the trial's topline results [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of 3D Systems Corporation during the specified Class Period of the upcoming lead plaintiff deadline on August 12, 2025, and the potential for compensation without out-of-pocket costs through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought 3D Systems securities between August 13, 2024, and May 12, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 12, 2025 [2][6]. - The lawsuit alleges that 3D Systems made false and misleading statements regarding its business performance and the impact of customer spending, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased iRobot Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline on September 5, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought iRobot securities between January 29, 2024, and March 11, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by the September 5, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm achieved the largest securities class action settlement against a Chinese company at the time and has consistently ranked among the top firms for securities class action settlements since 2013 [3]. Group 3: Case Allegations - The lawsuit alleges that iRobot made false and misleading statements regarding its Restructuring Plan and its ability to operate profitably as a standalone company after the termination of the Amazon Acquisition [4]. - It is claimed that there was substantial doubt about iRobot's ability to continue as a going concern, and that the defendants' public statements were materially false and misleading throughout the Class Period [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025, about the upcoming lead plaintiff deadline on September 26, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Lockheed Martin securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 26, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Lockheed Martin - The lawsuit alleges that Lockheed Martin made false and misleading statements and failed to disclose critical information regarding its internal controls and risk management practices [5]. - Specific claims include Lockheed Martin's inability to accurately report its risk-adjusted profit booking rate and its overstated capabilities in fulfilling contract commitments [5]. - The lawsuit asserts that these misrepresentations led to significant investor losses when the true details became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Neogen Corporation common stock between January 5, 2023, and June 3, 2025, of the September 16, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Neogen common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the court by September 16, 2025, to represent other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that Neogen's defendants made false and misleading statements about the integration process, claiming it was progressing smoothly when it was not [4] - Initially, defendants stated that the integration was "off to a great start" and that Neogen was experiencing solid core growth and profitability [4] - Despite acknowledging certain "inefficiencies" during the integration, defendants downplayed these issues, leading to investor damages when the true situation was revealed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought Flywire securities between February 28, 2024, and February 25, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 23, 2025 [3]. - The lawsuit alleges that Flywire's management made false and misleading statements regarding the sustainability of revenue growth and the impact of permit and visa-related restrictions on the business [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].